Effect of Onset-to-Admission Time and Care Bundle Achievement on Functional Outcomes in Patients With ICH A Population-Based Study
Por:
Lambea-Gil Á, Marti-Fabregas J, Cardona P, Rodriguez-Luna D, Millán M, Amaro S, Prats-Sanchez L, Silva Y, Seró L, Rodriguez-Campello A, Cánovas D, Martinez-Domeño A, Guasch-Jiménez M, Ezcurra-Díaz G, Carcel-Marquez J, Fernandez-Cadenas I, Pérez De La Ossa N, Abilleira S, Salvat-Plana M, Fagundez O, Camps-Renom P and Ramos-Pachón A
Publicada:
21 oct 2025
Ahead of Print:
30 sep 2025
Resumen:
Background and Objectives
Intracerebral hemorrhage (ICH) remains a leading cause of morbidity and mortality, with limited effective treatments. Early implementation of a care bundle protocol (CBP) within 6 hours of symptom onset has been shown to improve functional outcomes, although its effect beyond this time frame remains unclear. We assessed the impact of onset-to-admission (OTA) time and CBP achievement on functional outcome and mortality in patients with acute spontaneous ICH.
Methods
We conducted a population-based study of a prospective cohort of consecutive patients diagnosed with acute spontaneous ICH between 2020 and 2022 in Catalonia, Spain. Inclusion criteria were patients aged 18 years or older, OTA time <24 hours, and a baseline modified Rankin Scale (mRS) score <= 3. CBP achievement was defined as attaining control in the first 24 hours of blood pressure (<140/90 mm Hg), glycemia (<150 mg/dL), body temperature (<37.5 degrees C), and blood oxygen saturation (>92%) and, if required, anticoagulation reversal. The primary outcome was the proportion of patients with a favorable functional outcome, defined as mRS score <= 3 at 3-month follow-up. The effects of OTA time and CBP achievement on outcomes were evaluated using multivariable logistic regression. Potential interaction between OTA time and CBP achievement was assessed using the likelihood ratio test.
Results
A total of 1,821 patients were included (mean age 70.3 +/- 14.1 years, 37.7% women). CBP was achieved in 27.7% of patients. Shorter OTA time was independently associated with poorer functional outcome (adjusted odds ratio [aOR](x1h) 1.04, 95% CI 1.02-1.06). CBP achievement was associated with a higher probability of favorable outcome at 3 months (aOR 1.66, 95% CI 1.29-2.15). An interaction between OTA time and CBP achievement was observed (p = 0.016), indicating greater CBP benefits for earlier admission. This interaction was evident up to 13.8 hours after symptom onset, with the CBP benefit concentrated in the first 8 hours.
Discussion
Our findings highlight the importance of timely CBP application to improve functional outcome in patients with ICH, even beyond the first 6 hours after symptom onset. While earlier intervention remains ideal, our results support expanding CBP implementation and promoting "Code ICH" initiatives to enhance patient outcomes in stroke care systems.
Filiaciones:
Lambea-Gil Á:
Stroke Unit, Department of Neurology, Hospital de la Santa Creu i Sant Pau, Barcelona, Spain
Institut de Recerca Sant Pau (IR SANT PAU), Barcelona, Spain
Department of Medicine, Universitat Autònoma de Barcelona, Spain
Marti-Fabregas J:
Stroke Unit, Department of Neurology, Hospital de la Santa Creu i Sant Pau, Barcelona, Spain
Institut de Recerca Sant Pau (IR SANT PAU), Barcelona, Spain
Department of Medicine, Universitat Autònoma de Barcelona, Spain
Cardona P:
Stroke Unit, Department of Neurology, Hospital Universitari de Bellvitge, L'Hospitalet de Llobregat, Spain
Rodriguez-Luna D:
Stroke Unit, Department of Neurology, Hospital Universitari Vall d'Hebron, Barcelona, Spain
Stroke Research Group, Vall d'Hebron Research Institute, Barcelona, Spain
:
Neurology Service, Neurosciences Department, Hospital Germans Trias i Pujol, Badalona, Spain
Germans Trias i Pujol Research Institute (IGTP), Badalona, Spain
Amaro S:
Comprehensive Stroke Center, Department of Neuroscience, Hospital Clínic de Barcelona, Spain
Institut d'Investigacions Biomèdiques August Pi i Sunyer, Barcelona, Spain
Prats-Sanchez L:
Stroke Unit, Department of Neurology, Hospital de la Santa Creu i Sant Pau, Barcelona, Spain
Institut de Recerca Sant Pau (IR SANT PAU), Barcelona, Spain
Silva Y:
Department of Neurology, Hospital Universitari Dr. Josep Trueta, Girona, Spain
Department of Medicine, Universitat de Girona, Spain
Cerebrovascular Pathology Group, IDIBGI, Girona, Spain
Seró L:
Stroke Unit, Department of Neurology, Hospital Universitari Joan XXIII de Tarragona, Spain
Rodriguez-Campello A:
Stroke Unit, Department of Neurology, Hospital Del Mar, Barcelona, Spain
Cánovas D:
Stroke Unit, Department of Neurology, Hospital Universitari Parc Taulí, Sabadell, Spain
Martinez-Domeño A:
Stroke Unit, Department of Neurology, Hospital de la Santa Creu i Sant Pau, Barcelona, Spain
Institut de Recerca Sant Pau (IR SANT PAU), Barcelona, Spain
Guasch-Jiménez M:
Stroke Unit, Department of Neurology, Hospital de la Santa Creu i Sant Pau, Barcelona, Spain
Institut de Recerca Sant Pau (IR SANT PAU), Barcelona, Spain
Ezcurra-Díaz G:
Stroke Unit, Department of Neurology, Hospital de la Santa Creu i Sant Pau, Barcelona, Spain
Institut de Recerca Sant Pau (IR SANT PAU), Barcelona, Spain
Carcel-Marquez J:
Stroke Pharmacogenomics and Genetics Research Group, Institut de Recerca Sant Pau (IR SANT PAU), Barcelona, Spain
Fernandez-Cadenas I:
Stroke Pharmacogenomics and Genetics Research Group, Institut de Recerca Sant Pau (IR SANT PAU), Barcelona, Spain
:
Stroke Unit, Department of Neurology, Hospital de la Santa Creu i Sant Pau, Barcelona, Spain
Neurology Service, Neurosciences Department, Hospital Germans Trias i Pujol, Badalona, Spain
Stroke Programme, Health Department of Catalonia, Barcelona, Spain
Abilleira S:
Stroke Programme, Health Department of Catalonia, Barcelona, Spain
Salvat-Plana M:
Stroke Programme, Health Department of Catalonia, Barcelona, Spain
Agency for Health Quality and Assessment of Catalonia (AQUAS), Barcelona, Spain
and
CIBER Epidemiology and Public Health, Barcelona, Spain
Fagundez O:
Neurology Service, Neurosciences Department, Hospital Germans Trias i Pujol, Badalona, Spain
Agency for Health Quality and Assessment of Catalonia (AQUAS), Barcelona, Spain
and
Camps-Renom P:
Stroke Unit, Department of Neurology, Hospital de la Santa Creu i Sant Pau, Barcelona, Spain
Institut de Recerca Sant Pau (IR SANT PAU), Barcelona, Spain
Ramos-Pachón A:
Stroke Unit, Department of Neurology, Hospital de la Santa Creu i Sant Pau, Barcelona, Spain
Institut de Recerca Sant Pau (IR SANT PAU), Barcelona, Spain
Department of Medicine, Universitat Autònoma de Barcelona, Spain
|